SCHEMBL18325638

SCHEMBL18325638

CN(Cc1cc(O)cc(C#N)c1)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
CTSS P25774 3/20 0.38
CTSL P07711 2/20 0.38
CTSB P07858 2/20 0.38
HTR2C P28335 4/20 0.36
SLC6A4 P31645 4/20 0.36
CACNA1G O43497 1/20 0.35
CACNA1B Q00975 1/20 0.35
CACNA1C Q13936 1/20 0.35
NSD2 O96028 1/20 0.35
GLS O94925 1/20 0.34
ABCB1 P08183 3/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
HTR2A P28223 1/20 0.32
TACR1 P25103 1/20 0.31
CTSK P43235 1/20 0.31
PDK1 Q15118 1/20 0.31
PDK2 Q15119 1/20 0.31
PDK3 Q15120 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18325644 0.87 HTR2C (0.36) HSD17B1HSD17B2CTSSCTSLCTSB
SCHEMBL18325631 0.83 HTR2C (0.36) CTSSCTSLCTSBHTR2CSLC6A4
SCHEMBL320434 0.82 MEP1A (0.49) HSD17B1HSD17B2CTSSCTSLCTSB
SCHEMBL18325643 0.81 HTR2C (0.39) HSD17B1HSD17B2CTSSCTSLCTSB
SCHEMBL7233237 0.81 NSD2 (0.53) HSD17B1HSD17B2CTSSCTSLCTSB
SCHEMBL16629778 0.81 GPR119 (0.38) CTSSCTSLCTSBHTR2CSLC6A4
SCHEMBL18327668 0.80 HTR2C (0.41) HTR2CSLC6A4CACNA1GCACNA1BCACNA1C
SCHEMBL18327666 0.80 CALM1 (0.46) HSD17B1HSD17B2HTR2CSLC6A4CACNA1G
SCHEMBL18327669 0.80 RIPK1 (0.40) HSD17B1HSD17B2CTSSCTSLCTSB
SCHEMBL379928 0.78 CACNA1G (0.37) CTSSCTSLCTSBHTR2CSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9783500-B2 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition NORTHWESTERN UNIVERSITY (US) 2017-10-10 US disclosed
US-9783500-B2 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition NORTHWESTERN UNIVERSITY (US) 2017-10-10 US disclosed
US-20160368877-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed
US-20160368877-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368877-A1 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition NOS2, NOS3, NOS1 HSD17B1 2156/4885HSD17B2 2060/4885CTSS 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.